NO20072431L - Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater - Google Patents

Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater

Info

Publication number
NO20072431L
NO20072431L NO20072431A NO20072431A NO20072431L NO 20072431 L NO20072431 L NO 20072431L NO 20072431 A NO20072431 A NO 20072431A NO 20072431 A NO20072431 A NO 20072431A NO 20072431 L NO20072431 L NO 20072431L
Authority
NO
Norway
Prior art keywords
phenylmethylsulfonamide
benzohydryl
azetidin
intermediates
derivatives
Prior art date
Application number
NO20072431A
Other languages
English (en)
Norwegian (no)
Inventor
Luc Grondard
Stephane Mutti
Jorg Rieke-Zapp
Joel Malpart
Philippe Boffelli
Michel Delthil
Maxime Lampilas
Lahlou Nait Bouda
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20072431L publication Critical patent/NO20072431L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20072431A 2004-10-14 2007-05-11 Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater NO20072431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410845A FR2876689B1 (fr) 2004-10-14 2004-10-14 Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
PCT/FR2005/002489 WO2006040464A1 (fr) 2004-10-14 2005-10-10 Procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide

Publications (1)

Publication Number Publication Date
NO20072431L true NO20072431L (no) 2007-07-04

Family

ID=34953744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072431A NO20072431L (no) 2004-10-14 2007-05-11 Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater

Country Status (32)

Country Link
US (3) US7429668B2 (pt)
EP (1) EP1802571B1 (pt)
JP (1) JP4971986B2 (pt)
KR (1) KR20070063540A (pt)
CN (1) CN101039903A (pt)
AR (1) AR051389A1 (pt)
AT (1) ATE534624T1 (pt)
AU (1) AU2005293453A1 (pt)
BR (1) BRPI0516526A (pt)
CA (1) CA2581781A1 (pt)
CR (1) CR9008A (pt)
CY (1) CY1112390T1 (pt)
DK (1) DK1802571T3 (pt)
EA (2) EA200801990A1 (pt)
ES (1) ES2378181T3 (pt)
FR (1) FR2876689B1 (pt)
HR (1) HRP20120168T1 (pt)
IL (1) IL182277A0 (pt)
MA (1) MA29005B1 (pt)
ME (1) ME01297B (pt)
MX (1) MX2007004483A (pt)
NO (1) NO20072431L (pt)
PL (1) PL1802571T3 (pt)
PT (1) PT1802571E (pt)
RS (1) RS52132B (pt)
SG (2) SG144921A1 (pt)
SI (1) SI1802571T1 (pt)
TN (1) TNSN07115A1 (pt)
TW (1) TW200626542A (pt)
UY (1) UY29165A1 (pt)
WO (1) WO2006040464A1 (pt)
ZA (1) ZA200703011B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925050B1 (fr) * 2007-12-14 2010-01-08 Sanofi Aventis Nouveau procede de preparation de derives d'azetidine
EP2448909B1 (en) * 2009-06-29 2013-05-01 Merz Pharma GmbH & Co. KGaA Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
WO2011000538A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
CN107089918B (zh) * 2017-04-08 2020-06-16 迪嘉药业集团有限公司 一种盐酸二苯甲胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Also Published As

Publication number Publication date
CR9008A (es) 2007-10-01
AU2005293453A1 (en) 2006-04-20
UY29165A1 (es) 2006-05-31
US7429668B2 (en) 2008-09-30
WO2006040464A1 (fr) 2006-04-20
MA29005B1 (fr) 2007-11-01
EP1802571B1 (fr) 2011-11-23
US20100087414A1 (en) 2010-04-08
ZA200703011B (en) 2009-09-30
US20070244084A1 (en) 2007-10-18
US8071788B2 (en) 2011-12-06
SG144920A1 (en) 2008-08-28
AR051389A1 (es) 2007-01-10
CA2581781A1 (fr) 2006-04-20
TW200626542A (en) 2006-08-01
HRP20120168T1 (hr) 2012-03-31
US20080312205A1 (en) 2008-12-18
ES2378181T3 (es) 2012-04-09
CY1112390T1 (el) 2015-12-09
FR2876689B1 (fr) 2008-02-22
PT1802571E (pt) 2012-03-05
BRPI0516526A (pt) 2008-09-09
ME01297B (me) 2013-12-20
US7652154B2 (en) 2010-01-26
JP2008516931A (ja) 2008-05-22
EA200801990A1 (ru) 2009-06-30
EA012523B1 (ru) 2009-10-30
EA200700842A1 (ru) 2007-08-31
SI1802571T1 (sl) 2012-03-30
TNSN07115A1 (fr) 2008-06-02
FR2876689A1 (fr) 2006-04-21
PL1802571T3 (pl) 2012-04-30
RS52132B (sr) 2012-08-31
MX2007004483A (es) 2007-06-13
IL182277A0 (en) 2007-07-24
CN101039903A (zh) 2007-09-19
KR20070063540A (ko) 2007-06-19
EP1802571A1 (fr) 2007-07-04
JP4971986B2 (ja) 2012-07-11
DK1802571T3 (da) 2012-03-12
ATE534624T1 (de) 2011-12-15
SG144921A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
NO20071937L (no) Fremgangsmater og mellomprodukter for fremstilling av cysteinproteaseinhibitorer
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
NO20070130L (no) Farmasoytiske sammensetninger
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DK1701946T3 (da) 1-piperazin- og 1-homopiperazincarboxylatderivater, deres fremstilling og deres terapeutiske anvendelse som inhibitorer af FAAH-enzymet
NO20055562L (no) Substituerte indolin- og indolderivater
NO20071438L (no) 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser
CY1106544T1 (el) Μεθοδος συνθεσεως υπερινδοπριλης και τα φαρμακευτικως αποδεκτα αλατα αυτης
CY1106471T1 (el) Νεα μεθοδος συνθεσης της περινδροπριλης και των φαρμακευτικως αποδεκτων αλατων αυτης
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
PT1528923E (pt) Derivados de n-((3-oxo-2,3-di-hidro-1h-isoindol-1-il)acetil)guanidina como inibidores de nhe-1 para o tratamento de enfarte e angina de peito
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
IL213615A0 (en) N-(5-substituted-2-nitrophenyl)amine derivatives and methods for the preparation of 6-substituted-1-methyl-1-h-benzimidazole derivatives utilizing the same
NO20072431L (no) Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
NO20051393L (no) Prosess og intermediater for fremstilling av tienopyrrol-derivater
NO20073276L (no) Metode for fremstilling av aminoetoksybenzylalkoholer
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
NO20054721L (no) Substituerte anilinderivater
EA200600454A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application